UK Markets close in 15 mins

Addex Therapeutics Ltd (ADXN)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
9.550.00 (0.00%)
As of 2:15PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.55
Open9.53
Bid9.43 x 1300
Ask9.65 x 1200
Day's range9.40 - 9.55
52-week range8.56 - 37.52
Volume35
Avg. volume5,771
Market cap72.191M
Beta (5Y monthly)1.41
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?

    Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.

  • Globe Newswire

    Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

    Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021. Mr. Dyer will give a corporate update, including an overview of recent advances in Addex’s clinical trial program. The conference is free to all registrants. Registration DetailsDate: W

  • Globe Newswire

    Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

    Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization using computer aided drug discovery toolsAddex existing mGlu2 positive allosteric modulator, ADX71149, in clinical studies for epilepsy and mGlu2 negative allosteric modulators in preclinical development for neurocognitive disorders Geneva, Switzerland, July 1, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug dis